ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Distribution Services

Alfresa Holdings Corp.

Business Summary

Alfresa Holdings Corp. engages in the management of its subsidiaries that deal with wholesaling, manufacturing, import, and export of pharmaceutical products, diagnostic reagents, and medical devices. It operates through the following segments: Ethical Pharmaceuticals Wholesaling, Self-Medication Products Wholesaling, Manufacturing, and Medical-related. The Ethical Pharmaceuticals Wholesaling segment provides wholesale prescription drugs, medical diagnostic reagents, medical devices, equipment, and materials to hospitals, clinics, dispensing pharmacies, and other institutions. The Self-Medication Products Wholesaling segment sells over-the-counter drugs, health food, and supplements. The Manufacturing segment manufactures and markets pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices. The Medical-related segment offers medical services through its dispensing pharmacies. The company was founded on September 29, 2003 and is headquartered in Tokyo, Japan.

Financial Highlights

Mar 2022 JPYUSD
Gross Profit178,311M1,586.78M
Operating income29,092M258.88M
Income before tax48,180M428.75M
Net income32,182M286.38M
Diluted EPS153.571.36
Dividends Per Share540.48
Total Assets1,303.99B10,743.48M
Total liabilities832,152M6,856.04M
Total equity471,594M3,885.42M
Operating cash flow36,546M325.22M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 2,602.92B 2,640.52B 2,698.55B 2,610.52B 2,585.64B
Gross Profit 186,871M 194,456M 199,248M 174,676M 178,311M
Operating income 41,757M 44,784M 47,646M 27,931M 29,092M
Income before tax 51,567M 61,238M 59,233M 36,531M 48,180M
Net income 35,590M 41,725M 40,273M 24,500M 32,182M
EBITDA 52,321M 55,540M 59,423M 39,799M 41,916M
Diluted EPS 164.24 195.90 190.26 115.74 153.57
Dividends Per Share 39 48 50 53 54
Total Assets 1,337.45B 1,341.96B 1,351.61B 1,316.65B 1,303.99B
Total liabilities 901,512M 899,879M 876,715M 826,694M 832,152M
Total equity 434,769M 440,924M 473,702M 489,736M 471,594M
Operating cash flow 47,575M 46,880M 33,828M -21,191M 36,546M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 23,485.23M 23,811.14M 24,819.82M 24,614.22M 23,009.53M
Gross Profit 1,686.06M 1,753.51M 1,832.57M 1,646.99M 1,586.78M
Operating income 376.75M 403.84M 438.22M 263.35M 258.88M
Income before tax 465.26M 552.21M 544.79M 344.44M 428.75M
Net income 321.11M 376.25M 370.40M 231.00M 286.38M
EBITDA 472.07M 500.83M 546.54M 375.25M 373.00M
Diluted EPS 1.48 1.76 1.74 1.09 1.36
Dividends Per Share 0.35 0.43 0.45 0.49 0.48
Total Assets 12,575.92M 12,124.17M 12,520.20M 11,915.45M 10,743.48M
Total liabilities 8,476.83M 8,130.09M 8,121.11M 7,481.39M 6,856.04M
Total equity 4,088.09M 3,983.59M 4,387.95M 4,432.00M 3,885.42M
Operating cash flow 429.25M 422.74M 311.13M -199.80M 325.22M

Valuation Measures

Mar 2022
Operating margin1.12%
Profit margin1.24%

Key executives

  • President & Representative Director: Ryuji Arakawa
  • Director, Vice President & Head-Financial Planning: Seiichi Kishida
  • Director, Head-Compliance & Personnel Planning: Toshiki Tanaka
  • Director, VP & Head-Ethical Drug Wholesale: Yusuke Fukujin
  • Executive Officer & Manager-Audit: Yuji Ueda


  • Silchester International Investors LLP (11.3%)
  • Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.8%)
  • Nomura Asset Management Co., Ltd. (3.7%)
  • Alfresa Holdings Employee Stock Ownership Plan (2.8%)
  • The Vanguard Group, Inc. (2.1%)
  • Daiichi Sankyo Pension Fund (1.9%)
  • Daiwa Asset Management Co. Ltd. (1.6%)
  • Nikko Asset Management Co., Ltd. (1.6%)
  • Daiichi Sankyo Co., Ltd. (1.5%)
  • Norges Bank Investment Management (1.3%)

Contact Details

  • Website:
  • Address: Ote Center Building, 23/F, 1-1-3 Otemachi, Tokyo, 100-0004, Japan
  • Phone: +81.3.5219.5100

Related Companies

  • Alfresa Holdings Board Incentive Plan
  • Donut Robotics KK
  • Alfresa Fine Chemical Corp.
  • Sannova Co., Ltd. /Pharmaceutical Business/
  • Qingdao Nesco Medical Co. Ltd.
  • Alfresa System Corp.
  • Alfresa Healthcare Corp.
  • Alfresa Nikkensangyo KK
  • Shikoku Alfresa Corp.
  • Alfresa Pharma Corp.
  • Nissho Butsuryu Service Co. Ltd.
  • Sannova Co. Ltd.
  • Alfresa Medical Service Corp.
  • Shinohara Kagaku Yakuhin KK
  • Tampei Nakata Co. Ltd.
  • Apollo Medical Holdings Co., Ltd.
  • Ryuyaku KK
  • Nihon Apoch Co., Ltd
  • Ando Co., Ltd.
  • CS Yakuhin Co. Ltd.
  • Meisyo, Inc.
  • Kowa Yakuhin Co. Ltd.
  • Alfresa Holdings Employee Stock Ownership Plan
  • Taishodo Co Ltd
  • Odashima Ltd.
  • Daiwa Yakuhin Co Ltd
  • Alfresa Corp.
  • Ts Alfresa Corp.


    Last Updated on 4 Oct, 2022

    Discover the all new Nikkei Asia app

    • Take your reading anywhere with offline reading functions
    • Never miss a story with breaking news alerts
    • Customize your reading experience

    Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

    Celebrate our next chapter
    Free access for everyone - Sep. 30

    Find out more